{
    "pmcid": "8724751",
    "qa_pairs": {
        "How can nanobodies be engineered to enhance their effectiveness against SARS-CoV-2?": [
            "By linking them to form multivalent constructs",
            "By increasing their molecular weight",
            "By reducing their solubility",
            "By decreasing their binding affinity"
        ],
        "What is a key characteristic of nanobodies that makes them suitable for targeting viral proteins like the SARS-CoV-2 spike protein?": [
            "Their small size and stability",
            "Their ability to bind to multiple viruses simultaneously",
            "Their ability to change shape to fit different epitopes",
            "Their high mutation rate allowing rapid adaptation"
        ],
        "What is one potential therapeutic application of nanobodies mentioned in the context of SARS-CoV-2?": [
            "Inhalation therapy targeting the respiratory tract",
            "Oral administration for systemic infection",
            "Topical application for skin infections",
            "Intravenous injection for cardiovascular diseases"
        ],
        "What structural studies have provided insights into the cross-reactivity of nanobodies with SARS-CoV-2 variants?": [
            "Cryo-EM and X-ray crystallography",
            "NMR spectroscopy and mass spectrometry",
            "Fluorescence microscopy and electron tomography",
            "Atomic force microscopy and Raman spectroscopy"
        ],
        "Which production method is highlighted as advantageous for nanobodies in the context of rapid deployment during pandemics?": [
            "Production in microbial systems",
            "Synthesis in mammalian cell cultures",
            "Extraction from human plasma",
            "Chemical synthesis in vitro"
        ]
    }
}